Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Giugliano, D.
Right arrow Articles by D'Onofrio, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Giugliano, D.
Right arrow Articles by D'Onofrio, F.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes Care, Vol 21, Issue 4 631-636, Copyright © 1998 by American Diabetes Association

ARTICLES

Effects of perindopril and carvedilol on endothelium-dependent vascular functions in patients with diabetes and hypertension

D Giugliano, R Marfella, R Acampora, R Giunta, L Coppola and F D'Onofrio
Department of Geriatrics and Metabolic Diseases, Second University of Naples, Italy.

OBJECTIVE: To compare the effects of the ACE inhibitor perindopril and the beta-blocker carvedilol on blood pressure and endothelial functions in NIDDM patients with hypertension. RESEARCH DESIGN AND METHODS: We conducted a double-blind randomized trial in 26 patients with NIDDM and mild hypertension. A 4-week run-in placebo period preceded the active 12-week treatment with perindopril (4-8 mg daily) or carvedilol (25-50 mg daily). Endothelial functions were assessed by evaluating the hemodynamic (mean blood pressure, leg blood flow) and rheological (platelet aggregation, blood viscosity, and blood filterability) responses to an intravenous bolus of 3 g L-arginine, the natural precursor of nitric oxide. RESULTS: Both perindopril and carvedilol significantly reduced mean blood pressure (P < 0.001) and increased leg blood flow (P < 0.05) to the same extent; blood filterability remained unchanged in both perindopril- and carvedilol-treated groups. Carvedilol reduced platelet aggregation and blood viscosity significantly (P < 0.05) but perindopril did not. Before treatment, the hemodynamic and rheologic responses to L-arginine were significantly lower in patients (P < 0.05-0.01) than in 20 nondiabetic nonhypertensive control subjects. After 12 weeks of treatment, both drugs normalized the hemodynamic responses to L-arginine. Platelet aggregation response to L-arginine was ameliorated by carvedilol and remained unchanged in the perindopril group. CONCLUSIONS: At the doses used, both drugs effectively reduce blood pressure and normalize the hemodynamic responses to L-arginine. The implications of the ameliorated endothelial function for the poor cardiovascular outlook of the NIDDM hypertensive patient need further assessment.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Pharmacol. Rev.Home page
N. Toda, K. Ayajiki, and T. Okamura
Interaction of Endothelial Nitric Oxide and Angiotensin in the Circulation
Pharmacol. Rev., March 1, 2007; 59(1): 54 - 87.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
G. L. Bakris, V. Fonseca, R. E. Katholi, J. B. McGill, F. H. Messerli, R. A. Phillips, P. Raskin, J. T. Wright Jr, R. Oakes, M. A. Lukas, et al.
Metabolic Effects of Carvedilol vs Metoprolol in Patients With Type 2 Diabetes Mellitus and Hypertension: A Randomized Controlled Trial
JAMA, November 10, 2004; 292(18): 2227 - 2236.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Renin-Angiotensin-Aldosterone SystemHome page
R. Komers, R. Simkova, L. Kazdova, J. Ruzickova, and T. Pelikanova
Effects of ACE inhibition and AT1-receptor blockade on haemodynamic responses to L-arginine in Type 1 diabetes
Journal of Renin-Angiotensin-Aldosterone System, March 1, 2004; 5(1): 33 - 38.
[Abstract] [PDF]

Home page
 HypertensionHome page
P. G. Fegan, J. E. Tooke, K. M. Gooding, J. M. Tullett, K. M. MacLeod, and A. C. Shore
Capillary Pressure in Subjects With Type 2 Diabetes and Hypertension and the Effect of Antihypertensive Therapy
Hypertension, May 1, 2003; 41(5): 1111 - 1117.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
M. G. Modena, L. Bonetti, F. Coppi, F. Bursi, and R. Rossi
Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women
J. Am. Coll. Cardiol., August 7, 2002; 40(3): 505 - 510.
[Abstract] [Full Text] [PDF]

Home page
 Crit Care NurseHome page
M. Taccetta-Chapnick
Using Carvedilol to Treat Heart Failure
Crit. Care Nurse, April 1, 2002; 22(2): 36 - 58.
[Full Text] [PDF]

Home page
 JAMAHome page
J. C. Chambers, L. Fusi, I. S. Malik, D. O. Haskard, M. De Swiet, and J. S. Kooner
Association of Maternal Endothelial Dysfunction With Preeclampsia
JAMA, March 28, 2001; 285(12): 1607 - 1612.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
D.W. Laight, M.J. Carrier, and E.E. Anggard
Antioxidants, diabetes and endothelial dysfunction
Cardiovasc Res, August 18, 2000; 47(3): 457 - 464.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
P. C. Deedwania
Endothelium: a new target for cardiovascular therapeutics
J. Am. Coll. Cardiol., January 1, 2000; 35(1): 67 - 70.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1998 by the American Diabetes Association.